DB:6DW

Stock Analysis Report

D. Western Therapeutics Institute

Executive Summary

D. Western Therapeutics Institute, Inc., a biotechnology company, focuses on developing drugs to serve patients worldwide.


Snowflake Analysis

Excellent balance sheet with acceptable track record.

Share Price & News

How has D. Western Therapeutics Institute's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 6DW's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-12.4%

6DW

-2.3%

DE Biotechs

-0.2%

DE Market


1 Year Return

-14.2%

6DW

8.4%

DE Biotechs

13.7%

DE Market

Return vs Industry: 6DW underperformed the German Biotechs industry which returned 9% over the past year.

Return vs Market: 6DW underperformed the German Market which returned 14.4% over the past year.


Shareholder returns

6DWIndustryMarket
7 Day-12.4%-2.3%-0.2%
30 Day-14.3%-3.2%0.3%
90 Day26.3%6.3%3.7%
1 Year-14.2%-14.2%8.6%8.4%17.2%13.7%
3 Year-31.0%-31.0%44.5%42.9%15.4%5.3%
5 Year-33.6%-33.6%13.0%10.6%21.3%4.7%

Price Volatility Vs. Market

How volatile is D. Western Therapeutics Institute's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is D. Western Therapeutics Institute undervalued compared to its fair value and its price relative to the market?

95.82x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: 6DW (€3.94) is trading above our estimate of fair value (€3.25)

Significantly Below Fair Value: 6DW is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 6DW is poor value based on its PE Ratio (95.8x) compared to the Biotechs industry average (39.4x).

PE vs Market: 6DW is poor value based on its PE Ratio (95.8x) compared to the German market (20.7x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 6DW's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 6DW is overvalued based on its PB Ratio (9.1x) compared to the DE Biotechs industry average (3.6x).


Next Steps

Future Growth

How is D. Western Therapeutics Institute forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

35.5%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as D. Western Therapeutics Institute has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has D. Western Therapeutics Institute performed over the past 5 years?

21.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 6DW has high quality earnings.

Growing Profit Margin: 6DW became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: 6DW has become profitable over the past 5 years, growing earnings by 21% per year.

Accelerating Growth: 6DW has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: 6DW has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: 6DW's Return on Equity (7.7%) is considered low.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is D. Western Therapeutics Institute's financial position?


Financial Position Analysis

Short Term Liabilities: 6DW's short term assets (¥1.7B) exceed its short term liabilities (¥189.0M).

Long Term Liabilities: 6DW's short term assets (¥1.7B) exceed its long term liabilities (¥384.0M).


Debt to Equity History and Analysis

Debt Level: 6DW's debt to equity ratio (34.1%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if 6DW's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: 6DW has a low level of unsold assets or inventory.

Debt Coverage by Assets: 6DW's debt is covered by short term assets (assets are 3.6x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 6DW is profitable, therefore cash runway is not a concern.

Forecast Cash Runway: 6DW is profitable, therefore cash runway is not a concern.


Next Steps

Dividend

What is D. Western Therapeutics Institute's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.3%markettop25%3.7%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate 6DW's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 6DW's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 6DW's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 6DW's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 6DW's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

8.8yrs

Average board tenure


CEO

Hiroyoshi Hidaka (81yo)

0

Dr. Hiroyoshi Hidaka, M.D., Ph.D. founded D.Western Therapeutics Institute in 1999 and has been its Chairman since June 2012 and also has been chief Science Officer Since June, 2010 and serves as its Chief ...


Board Members

NamePositionTenureCompensationOwnership
Hiroyoshi Hidaka
Founder0yrsno data11.88% ¥12.5m
Yuichi Hidaka
President11.2yrsno data10.42% ¥11.0m
Tetsuya Kawakami
GM of Administration Division & Director5.9yrsno data0.0076% ¥8.0k
Yoshiyuki Yamakawa
Outside Director9.9yrsno datano data
Masaaki Suzuki
Member of Scientific Advisory Board0yrsno datano data
Tasuku Honjyo
Member of Scientific Advisory Board0yrsno datano data
Masato Shibuya
Member of Scientific Advisory Board0yrsno datano data
Arata Uemura
Member of Scientific Advisory Board0yrsno datano data
Anthony Means
Member of Scientific Advisory Board0yrsno datano data
Walter Chazin
Member of Scientific Advisory Board0yrsno datano data

8.8yrs

Average Tenure

55.5yo

Average Age

Experienced Board: 6DW's board of directors are considered experienced (8.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

D. Western Therapeutics Institute, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: D. Western Therapeutics Institute, Inc.
  • Ticker: 6DW
  • Exchange: DB
  • Founded: 1999
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: JP¥12.743b
  • Listing Market Cap: JP¥105.484m
  • Shares outstanding: 26.28m
  • Website: https://www.dwti.co.jp

Number of Employees


Location

  • D. Western Therapeutics Institute, Inc.
  • CK21 Hirokoujifushimi Building
  • 7th Floor
  • Nagoya
  • Aichi
  • 460-0003
  • Japan

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
4576JASDAQ (TSE JASDAQ)YesCommon SharesJPJPYOct 2009
6DWDB (Deutsche Boerse AG)YesCommon SharesDEEUROct 2009

Biography

D. Western Therapeutics Institute, Inc., a biotechnology company, focuses on developing drugs to serve patients worldwide. The company offers GLANATEC, an ophthalmic solution for the treatment of glaucoma/ocular hypertension; and DW-1002, an ophthalmic surgical adjuvant for cataract surgeries, and ILM staining and peeling. It is also developing WP-1303(H-1129), which is in Phase III clinical trials to treat glaucoma/ocular hypertension; H-1337, a multikinase inhibitor that has completed Phase I/IIa clinical trials for the treatment of glaucoma/ocular hypertension; and K-134, an anti-platelet, which has completed Phase IIb trials to treat arteriosclerosis obliterans. The company was founded in 1999 and is headquartered in Nagoya, Japan. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/20 21:43
End of Day Share Price2020/02/20 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.